Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Public ClinicalTrials.gov record NCT02499770. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.
Study identification
- NCT ID
- NCT02499770
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2015 (Actual)
- Primary completion
- Jul 3, 2017 (Actual)
- Completion
- Feb 22, 2019 (Actual)
- Last update posted
- Aug 21, 2020
2015 – 2019
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| Memorial Hospital - Univ. of Colorado Health | Colorado Springs | Colorado | 80909 | — |
| University of Colorado Health, Oncology Clinical Research Northern Region | Fort Collins | Colorado | 80528 | — |
| Boca Raton Regional Hospital - Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists - North | Tavares | Florida | 32778 | — |
| Florida Cancer Specialists - East | West Palm Beach | Florida | 33401 | — |
| University Cancer and Blood Center, LLC | Athens | Georgia | 30607 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Center For Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Roswell Park | Buffalo | New York | 14263 | — |
| UNC - Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | — |
| Oklahoma University - Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73117 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Guthrie Medical Group, PC | Sayre | Pennsylvania | 18840 | — |
| Greenville Health System | Greenville | South Carolina | 29605 | — |
| Gibbs Cancer Center | Spartanburg | South Carolina | 29203 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Hanna Cancer Associates - University of Tennessee | Knoxville | Tennessee | 37920 | — |
| Texas Oncology | Tyler | Texas | 75702 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02499770, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2020 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02499770 live on ClinicalTrials.gov.